Unit of PharmacoTherapy, Epidemiology, & Economics, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands.
Program Studi Farmasi, Fakultas Kedokteran, Universitas Tanjungpura, Pontianak, Indonesia.
Arch Womens Ment Health. 2023 Oct;26(5):685-696. doi: 10.1007/s00737-023-01355-8. Epub 2023 Aug 5.
The purpose of the study is to examine the switching pattern and dose adjustment of antidepressants (ADs) prescribed to women from six months before to six months during pregnancy in the Netherlands. The recorded dispenses or refills were collected from the University of Groningen IADB.nl pregnancy subset for all singleton pregnancies in which the mother received ≥ 1 prescription of an AD dispensed before pregnancy and was present in the database at least six months after conception. The rates of continuation, discontinuation, and switching between 2001 and 2020 were assessed for the ADs studied. The mean number of Defined Daily Doses (DDDs) of the most frequently continued ADs used was calculated both before and during pregnancy, and a paired t-test was used to test for significant changes. The continuation rates for AD users, especially for SSRI and SNRI continued users, increased over time from 27% and 19% (2001-2005) to 65% and 65% (2016-2020). The switching rate between ADs remained consistently low from the start of the study (2001-2005) at 2.0% to the end of the study (2016-2020) at 2.3%. Most women who switched between antidepressants during pregnancy received a different SSRI monotherapy (85%), followed by an SNRI (6%), a TCA (4%), and an "other AD" (4%). In most cases observed, the dose adjustment for the mean DDDs during pregnancy compared to the mean DDDs before pregnancy only changed little (less than 10%). Continued use of SSRIs among singleton pregnancies doubled over the study period. The low rate of AD switching and little changes in the DDD adjustment for most AD continuers indicate that pregnant women prefer to continue their prepregnancy medication rather than switch it. Most observed findings cohere with the Dutch national guidelines for antidepressant use during pregnancy.
这项研究的目的是检查荷兰女性在怀孕前六个月到怀孕后六个月期间抗抑郁药(ADs)的转换模式和剂量调整。从格罗宁根大学 IADB.nl 妊娠子集中收集了记录的配药或补药,这些配药或补药来自至少在受孕后六个月内存在于数据库中的所有单胎妊娠中,这些母亲在妊娠前接受了≥1 种 AD 处方且至少在受孕后六个月内存在于数据库中。评估了在 2001 年至 2020 年期间研究的 ADs 的继续使用、停止使用和转换率。计算了最常继续使用的 AD 之前和怀孕期间的平均每日定义剂量(DDD)数,并使用配对 t 检验检验是否有显著变化。AD 用户的继续使用率,尤其是 SSRI 和 SNRI 的继续使用率,随着时间的推移从 27%和 19%(2001-2005 年)增加到 65%和 65%(2016-2020 年)。从研究开始(2001-2005 年)到研究结束(2016-2020 年),AD 之间的转换率一直保持在较低水平(2.0%)。怀孕期间转换 AD 的大多数女性接受了不同的 SSRI 单药治疗(85%),其次是 SNRI(6%)、TCA(4%)和“其他 AD”(4%)。在大多数观察到的情况下,与妊娠前相比,怀孕期间平均 DDD 的剂量调整变化不大(小于 10%)。在研究期间,SSRI 在单胎妊娠中的继续使用率翻了一番。AD 继续使用者中 AD 转换率较低,大多数 AD 继续使用者的 DDD 调整变化不大,这表明孕妇更愿意继续使用妊娠前的药物,而不是转换药物。大多数观察到的发现与荷兰国家抗抑郁药使用指南一致。